Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients
Recruitment status was: Recruiting
Vascular access complications are the leading cause of morbidity in hemodialysis (HD) patients, and are responsible for a significant percentage of hospitalization, with annual costs approaching one billion dollars in the United States. Thrombosis is the most common cause of vascular access failure, and usually develops from stenotic lesions in the venous outflow tract. It has been reported that far infrared (FIR) therapy can improve access flow and unassisted patency of AV fistula, however, the effect of FIR on cardiac function is unknown.
The aims of this study are to evaluate (1) the change of access flow of AV fistula and the effect of AV fistula on echocardiographic parameters and (2) the effect of FIR on access flow of AVF and echocardiographic parameters and the serum levels of endothelial markers in patients with end stage renal disease (ESRD) during the first 6 months after the creation of AV fistula.
|End Stage Renal Disease||Device: WSTM TY101 FIR emitter (Far infrared therapy) Other: no intervention||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease|
- Access flow monthly for 3 months and 6th month (0,1st,2nd,3rd and 6th months) and Echocardiographic parameters at 6th month ( 0 and 6th months) [ Time Frame: 6 months ]Color Doppler ultrasonography was carried out to measure the access flow of AV fistula with commercially available equipment (Model SSA 340A; Toshiba, Tokyo, Japan). Echocardiographic parameters will be analysed according to the American Society of Echocardiography criteria with a Sonos 5500 sonographic system (Philips, Andover, MA, USA) incorporated with a multi-frequency transducer.Left atrial dimension was determined by M-mode echocardiography.
- Plasma asymmetric dimethyl arginine (ADMA) and L-arginine [ Time Frame: 6 months (every 3 months) ]Plasma L-arginine and ADMA concentrations were determined by HPLC using precolumn derivatization with o-phthaldialdehyde (OPA) at 0 (before creation of AVF), 3rd and 6th months after creation of AV fistula.
|Study Start Date:||November 2008|
|Estimated Study Completion Date:||August 2011|
|Estimated Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
No Intervention: control group
ESRD patients will not receive FIR therapy in this study.
Other: no intervention
Other Name: no intervention by FIR therapy
Experimental: Far infrared therapy
Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
Device: WSTM TY101 FIR emitter (Far infrared therapy)
A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
Other Name: Far infrared therapy (WSTM TY101 FIR emitter)
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01138254
|Contact: Hsiao-Di Cheng, BSc||+886-2-28712121 ext firstname.lastname@example.org|
|Taipei Veterans General Hospital||Recruiting|
|Taipei, Taiwan, 112|
|Contact: CHIH-CHING LIN, MD, PhD +886-2-28712121 ext 2970 email@example.com|
|Principal Investigator: CHIH-CHING LIN, MD;PhD|
|Principal Investigator:||CHIH-CHING LIN, MD, PhD||Taipei Veterans General Hospital, Taiwan|